TCGA-75-6203-01A-11R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.480
- KRAS_SIGNALING_UP+0.440
- COMPLEMENT+0.430
- INFLAMMATORY_RESPONSE+0.430
- ALLOGRAFT_REJECTION+0.400
- BILE_ACID_METABOLISM+0.390
- IL6_JAK_STAT3_SIGNALING+0.360
- PANCREAS_BETA_CELLS+0.350
- MYOGENESIS+0.340
- UV_RESPONSE_DN+0.320
Top 10 suppressed
- MYC_TARGETS_V2-0.760
- E2F_TARGETS-0.700
- MYC_TARGETS_V1-0.700
- G2M_CHECKPOINT-0.640
- DNA_REPAIR-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.500
- OXIDATIVE_PHOSPHORYLATION-0.480
- MTORC1_SIGNALING-0.460
- MITOTIC_SPINDLE-0.370
- GLYCOLYSIS-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-L4-A4E6-01A-11R-A24H-07 | — | cohortA1 | 0.945 |
| 2 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.944 |
| 3 | TCGA-CR-7391-01A-11R-2016-07 | — | — | 0.935 |
| 4 | TCGA-55-8621-01A-11R-2403-07 | — | cohortA1 | 0.934 |
| 5 | TCGA-56-8623-01A-11R-A28V-07 | — | cohortA1 | 0.929 |
| 6 | BS_BA6AZWB3 | Med | Medulloblastoma | 0.923 |
| 7 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.921 |
| 8 | TCGA-93-7347-01A-11R-2187-07 | — | cohortA1 | 0.920 |
| 9 | MDT-AP-3282 | Med | Medulloblastoma | 0.918 |
| 10 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.480 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |